Press Releases
June 06, 2016
Kite/NCI Anti-CD19 CAR T-Cell Therapy Demonstrates Durable Complete Remissions in Advanced Non-Hodgkin Lymphoma
9 of 19 patients (47%) with diffuse large B-cell lymphoma achieved complete responses, which are all ongoing with a duration of 7 to 20 months
In this study of 22 patients (19 diffuse large B-cell lymphoma, 2 follicular lymphoma, and 1 mantle cell lymphoma), objective responses were seen in 16 patients (73%). Twelve of 22 patients (55%) achieved complete responses following low-dose chemotherapy conditioning regimen. Kite is using a similar conditioning regimen in its ZUMA-1 Study of KTE-C19, an anti-CD19 CAR T cell therapy. Nine of 19 patients (47%) with diffuse large B-cell lymphoma (DLBCL) achieved complete responses, which are all ongoing with a duration of 7+ to 20+ months. Additionally, the three patients with mantle cell lymphoma and follicular lymphoma achieved complete responses. Reversible grade 3 or 4 neurotoxicity including confusion, dysphasia, encephalopathy, and gait disturbances was observed in 55% of treated patients.
"Patients with chemorefractory DLBCL have few effective treatment
options," said
According to the
This study was performed pursuant to a
About Kite Pharma
Cautionary Note on Forward-Looking Statements
This press
release contains forward-looking statements for purposes of the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will," "should"
or other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking statements
include statements regarding our intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the success of anti-CD19 CAR T cell therapy. Various factors may
cause differences between Kite's expectations and actual results as
discussed in greater detail in Kite's filings with the Securities and
Exchange Commission, including without limitation in Kite's Quarterly
Report on Form 10-Q filed with the SEC on May 9, 2016. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
References:
1.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160606005541/en/
VP, Investor Relations
gmann@kitepharma.com
or
For
Media:
inVentiv Health
david.polk@inventivhealth.com
or
anne.cummings@inventivhealth.com
Source:
News Provided by Acquire Media